FibroBiologics advances bone marrow organoid platform for cancer and immune therapies

FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, announced significant advancements in its Bone Marrow Organoid (BMO) platform, which may offer new treatment options for hematopoietic cancers and age-related immune decline. The company reported that pre-IND animal trials …